Netropsin
Based on 1 publication(s) in Google Scholar
Netropsin dihydrochloride is a small-molecule MGB (minor-groove binder) and antibiotic, inhibits the catalytic activity of isolated topoisomerase and interferes with the stabilization of the cleavable complexes of topoisomerase II and I in nuclei. Netropsin dihydrochloride has antibacterial and antiviral activity.
For research use only. We do not sell to patients.
- CAS No.: 1438-30-8
- Formula: C18H26N10O3
- Molecular Weight:430.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Netropsin
MoreAll Antibiotic Isoforms
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DC3F | IC50 |
3.2 mM
Compound: Netropsin
|
Cytotoxicity against hamster DC-3F cells
Cytotoxicity against hamster DC-3F cells
|
[PMID: 20471276] |
| HT-29 | IC50 |
44.7 μM
Compound: Netropsin
|
Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
|
[PMID: 9003520] |
| K562 | IC50 |
>50 μM
Compound: Netropsin
|
Cytotoxicity against human K562 cells after 72 hrs by MTS assay
Cytotoxicity against human K562 cells after 72 hrs by MTS assay
|
[PMID: 20471276] |
| KB | IC50 |
47.1 μM
Compound: Netropsin
|
Inhibitory concentration that reduced the viability of KB cell population by 50%.
Inhibitory concentration that reduced the viability of KB cell population by 50%.
|
[PMID: 9003520] |
| SK-VLB | IC50 |
>10 μM
Compound: Netropsin
|
Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
|
[PMID: 9003520] |
Chemical Information
-
CAS No. 1438-30-8
-
Molecular Weight 430.46
-
Formula C18H26N10O3
-
SMILES
O=C(C1=CC(NC(CNC(N)=N)=O)=CN1C)NC2=CN(C)C(C(NCCC(N)=N)=O)=C2
-
Structure Classification
-
Initial Source
Streptomyces netropsis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)